TY - JOUR
T1 - Influence of dopamine receptor and adrenoceptor blockade an the hemoconcentrating and hypotensive actions of atrial natriuretic peptide
AU - Valentin, Jean Pierre
AU - Ribstein, Jean
AU - Nafrialdi, null
AU - Mimran, Albert
PY - 1997
Y1 - 1997
N2 - Atrial natriuretic peptide (ANP) lowers mean arterial pressure (MAP) and increases hematocrit through reduction in plasma volume caused by a transcapillary shift of plasma fluid and protein toward the interstitium. We examined the consequences of blockade of the dopaminergic and adrenergic systems on the hypotensive and hemoconcentrating responses to ANP. Changes in MAP, hematocrit, and plasma protein concentration (PPC) were measured in anesthetized acutely binephrectomized rats, during infusion of ANP alone (1 μg·kg-1·min-1 for 45 min) or in the presence of haloperidol (20 μg·kg-1·min-1), phentolamine (15 μg/kg-1·min-1), or propranolol (10 μg·kg-1·min-1). Infusion of ANP reduced MAP by 8.6 ± 1.3% and increased hematocrit by 9.0 ± 0.6% (both p < 0.005 vs. vehicle). PPC increased (4.4 ± 0.6%; p < 0.005 vs. vehicle) significantly less than hematocrit, indicating extravasation of proteins. The ANP-evoked reduction in MAP was not affected in haloperidol- or phentolamine-treated rats (-8.8 ± 2.3 and -10.5 ± 2.4%, respectively; both p < 0.005 vs. vehicle) but was abolished in propranolol-treated rats (+3.2 ± 1.3%; p = ns vs. vehicle). The ANP-induced increase in hematocrit was slightly-attenuated in haloperidol-, phentolamine-, and propranolol-treated rats (7.5 ± 0.7, 7.3 ± 0.8, and 6.0 ± 1%, respectively). In addition, the coefficient of reflection, an index of the permeability to proteins, was higher in these three groups (0.41 ± 0.06, 0.49 ± 0.08, and 0.57 ± 0.14, respectively) than in control rats infused with ANP (0.27 ± 0.03), indicating an attenuation of the ANP-induced extravasation of proteins. Thus, in binephrectomized rats, the hypotensive activity of ANP requires a β-adrenergic component, whereas its hemoconcentrating action is, at least in part, dependent upon dopaminergic and adrenergic activation.
AB - Atrial natriuretic peptide (ANP) lowers mean arterial pressure (MAP) and increases hematocrit through reduction in plasma volume caused by a transcapillary shift of plasma fluid and protein toward the interstitium. We examined the consequences of blockade of the dopaminergic and adrenergic systems on the hypotensive and hemoconcentrating responses to ANP. Changes in MAP, hematocrit, and plasma protein concentration (PPC) were measured in anesthetized acutely binephrectomized rats, during infusion of ANP alone (1 μg·kg-1·min-1 for 45 min) or in the presence of haloperidol (20 μg·kg-1·min-1), phentolamine (15 μg/kg-1·min-1), or propranolol (10 μg·kg-1·min-1). Infusion of ANP reduced MAP by 8.6 ± 1.3% and increased hematocrit by 9.0 ± 0.6% (both p < 0.005 vs. vehicle). PPC increased (4.4 ± 0.6%; p < 0.005 vs. vehicle) significantly less than hematocrit, indicating extravasation of proteins. The ANP-evoked reduction in MAP was not affected in haloperidol- or phentolamine-treated rats (-8.8 ± 2.3 and -10.5 ± 2.4%, respectively; both p < 0.005 vs. vehicle) but was abolished in propranolol-treated rats (+3.2 ± 1.3%; p = ns vs. vehicle). The ANP-induced increase in hematocrit was slightly-attenuated in haloperidol-, phentolamine-, and propranolol-treated rats (7.5 ± 0.7, 7.3 ± 0.8, and 6.0 ± 1%, respectively). In addition, the coefficient of reflection, an index of the permeability to proteins, was higher in these three groups (0.41 ± 0.06, 0.49 ± 0.08, and 0.57 ± 0.14, respectively) than in control rats infused with ANP (0.27 ± 0.03), indicating an attenuation of the ANP-induced extravasation of proteins. Thus, in binephrectomized rats, the hypotensive activity of ANP requires a β-adrenergic component, whereas its hemoconcentrating action is, at least in part, dependent upon dopaminergic and adrenergic activation.
KW - Adrenoceptor
KW - Atrial natriuretic peptide
KW - Body fluid balance
KW - Dopamine receptor
KW - Plasma extravasation
KW - Plasma volume
KW - Receptor antagonism
KW - Vascular permeability
KW - Vasodilatation
UR - http://www.scopus.com/inward/record.url?scp=0030780238&partnerID=8YFLogxK
U2 - 10.1139/y97-134
DO - 10.1139/y97-134
M3 - Article
C2 - 9365827
AN - SCOPUS:0030780238
SN - 0008-4212
VL - 75
SP - 1142
EP - 1147
JO - Canadian Journal of Physiology and Pharmacology
JF - Canadian Journal of Physiology and Pharmacology
IS - 9
ER -